Investigation into the Manufacture and Properties of Inhalable High-Dose Dry Powders Produced by Comilling API and Lactose with Magnesium Stearate

被引:8
作者
Lau, Michael [1 ]
Young, Paul M. [1 ]
Traini, Daniela [1 ]
机构
[1] Univ Sydney, Resp Technol Grp, Woolcock Inst Med Res & Discipline Pharmacol, Sydney Med Sch, Sydney, NSW 2006, Australia
来源
AAPS PHARMSCITECH | 2017年 / 18卷 / 06期
关键词
comilling; dry powder; high-dose delivery; jet-mill; magnesium stearate; PULMONARY DRUG-DELIVERY; COATING APPROACH; LUBRICANT PROPERTIES; SALBUTAMOL SULFATE; IN-VITRO; DISPERSION; PARTICLES; INHALERS; FLOW; PERFORMANCE;
D O I
10.1208/s12249-016-0708-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the study was to understand the impact of different concentrations of the additive material, magnesium stearate (MGST), and the active pharmaceutical ingredient (API), respectively, on the physicochemical properties and aerosol performance of comilled formulations for high-dose delivery. Initially, blends of API/lactose with different concentrations of MGST (1-7.5% w/w) were prepared and comilled by the jet-mill apparatus. The optimal concentration of MGST in comilled formulations was investigated, specifically for agglomerate structure and strength, particle size, uniformity of content, surface coverage, and aerosol performance. Secondly, comilled formulations with different API (1-40% w/w) concentrations were prepared and similarly analyzed. Comilled 5% MGST (w/w) formulation resulted in a significant improvement in in vitro aerosol performance due to the reduction in agglomerate size and strength compared to the formulation comilled without MGST. Higher concentrations of MGST (7.5% w/w) led to reduction in aerosol performance likely due to excessive surface coverage of the micronized particles by MGST, which led to failure in uniformity of content and an increase in agglomerate strength and size. Generally, comilled formulations with higher concentrations of API increased the agglomerate strength and size, which subsequently caused a reduction in aerosol performance. High-dose delivery was achieved at API concentration of >20% (w/w). The study provided a platform for the investigation of aerosol performance and physicochemical properties of other API and additive materials in comilled formulations for the emerging field of high-dose delivery by dry powder inhalation.
引用
收藏
页码:2248 / 2259
页数:12
相关论文
共 48 条
  • [1] Influence of the physicochemical variability of magnesium stearate on its lubricant properties: Possible solutions
    Barra, J
    Somma, R
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1996, 22 (11) : 1105 - 1120
  • [2] The cohesive-adhesive balances in dry powder inhaler formulations II: Influence on fine particle delivery characteristics
    Begat, P
    Morton, DAV
    Staniforth, JN
    Price, R
    [J]. PHARMACEUTICAL RESEARCH, 2004, 21 (10) : 1826 - 1833
  • [3] Structural influence of cohesive mixtures of salbutamol sulphate and lactose on aerosolisation and de-agglomeration behaviour under dynamic conditions
    Behara, Srinivas Ravindra Babu
    Kippax, Paul
    McIntosh, Michelle P.
    Morton, David A. V.
    Larson, Ian
    Stewart, Peter
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 42 (03) : 210 - 219
  • [4] British Pharmacopeia Commission, 2016, APP 12 C CONS FORM P, VV, P2016
  • [5] Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler® in Comparison with Diskus® and Turbohaler® Dry Powder Inhalers
    Buttini, Francesca
    Brambilla, Gaetano
    Copelli, Diego
    Sisti, Viviana
    Balducci, Anna Giulia
    Bettini, Ruggero
    Pasquali, Irene
    [J]. JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2016, 29 (02) : 167 - 178
  • [6] Inhaled Insulin: A Breath of Fresh Air? A Review of Inhaled Insulin
    Cavaiola, Tricia Santos
    Edelman, Steven
    [J]. CLINICAL THERAPEUTICS, 2014, 36 (08) : 1275 - 1289
  • [7] Characterization of pharmaceutical powder inhalers: estimation of energy input for powder dispersion and effect of capsule device configuration
    Chew, NYK
    Chan, HK
    Bagster, DF
    Mukhraiya, J
    [J]. JOURNAL OF AEROSOL SCIENCE, 2002, 33 (07) : 999 - 1008
  • [8] Particle engineering for pulmonary drug delivery
    Chow, Albert H. L.
    Tong, Henry H. Y.
    Chattopadhyay, Pratibhash
    Shekunov, Boris Y.
    [J]. PHARMACEUTICAL RESEARCH, 2007, 24 (03) : 411 - 437
  • [9] Coates M, 2004, Respir Drug Deliv IX, V3, P821
  • [10] Dunbar CA., 1998, KONA, V16, P7, DOI DOI 10.14356/KONA.1998007